Shareholder Rights Plans – Kuwait Financial Express http://www.kuwaitfinancialexpress.com Tue, 12 Mar 2024 16:18:02 +0000 en-US hourly 1 https://wordpress.org/?v=5.3.2 Fortrea unterzeichnet endgültige Vereinbarung zur Veräußerung der Geschäftsbereiche Endpoint Clinical und Patient Access an Arsenal Capital Partners http://www.kuwaitfinancialexpress.com/?p=309910/ Tue, 12 Mar 2024 16:18:02 +0000 http://www.kuwaitfinancialexpress.com/?p=309910 Vorgeschlagene Veräußerung der Geschäftsbereiche Endpoint Clinical und Fortrea Patient Access optimiert Fortreas strategische Ausrichtung als reines Auftragsforschungsinstitut

Schafft eigenständige, erstklassige Lösungen für Randomisierung, Trial Supply Management und Patientenzugang, die für Differenzierung und Wachstum positioniert sind

DURHAM, North Carolina, March 12, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (das „Unternehmen“), ein weltweit führendes Auftragsforschungsinstitut (Contract Research Organization, CRO), gab heute die Unterzeichnung einer endgültigen Vereinbarung über die Veräußerung von Vermögenswerten des Segments Enabling Services, insbesondere der Geschäftsbereiche Endpoint Clinical („Endpoint“) und Fortrea Patient Access, an Arsenal Capital Partners („Arsenal“) bekannt, eine führende Private–Equity–Gesellschaft, die sich auf den Aufbau marktführender, technologieorientierter Unternehmen im Gesundheitswesen spezialisiert hat.

Durch die Veräußerung dieser Geschäftsbereiche möchte Fortrea die Wachstumsstrategie und die Lösungen von Endpoint und Fortrea Patient Access voranbringen und sie für höhere Investitionen positionieren, um die Technologie–Roadmap zu beschleunigen und die Betriebsabläufe weiter zu verbessern, um erstklassige Kundenlösungen und –lieferungen zu unterstützen. Das verbleibende Geschäft von Fortrea wird sich verstärkt auf die klinischen Entwicklungsphasen 1 bis 4 konzentrieren. Der Abschluss wird für das zweite Quartal 2024 angestrebt, vorbehaltlich der üblichen Abschlussbedingungen und behördlichen Genehmigungen sowie des Abschlusses bestimmter Dienstleistungs– und Betriebsvereinbarungen zwischen den Parteien.

„Der heutige Tag markiert einen bedeutenden Meilenstein für die Zukunft von Fortrea. Denn wir konzentrieren uns verstärkt auf das organische Wachstum eines reinen Auftragsforschungsinstituts, das über zusätzliche finanzielle Flexibilität verfügt“, sagte Tom Pike, Vorsitzender und CEO von Fortrea. „Nach einer strategischen Überprüfung unseres Geschäfts steht die Veräußerung von Endpoint und Fortrea Patient Access im Einklang mit den Interessen unserer Kunden. Arsenal verfügt über umfassende Erfahrung im Aufbau von Unternehmen, die systematische Verbesserungen der Gesundheitsergebnisse bewirken, und ich bin zuversichtlich, dass Endpoint und Fortrea Patient Access in der Lage sein werden, ihre Marktposition zu stärken, erstklassige Talente zu fördern und in neue Fähigkeiten und Ressourcen zu investieren, während sie Lösungen anbieten, die das Leben der Patienten verbessern.“

„Ich bin gespannt auf das nächste Kapitel für Endpoint und Fortrea Patient Access“, sagte Sam Osman, President von Enabling Services bei Fortrea, der als CEO dieser Unternehmen bei Arsenal fungieren wird. „Diese Unternehmen sind besonders gut positioniert, um den Weg der Patienten von der klinischen Prüfung bis zur Vermarktung effektiv zu begleiten, indem sie den Zugang der Patienten zu zugelassenen Therapien und die Patientenadhärenz fördern. Ich bin zuversichtlich, dass die Geschäftsbereiche Endpoint und Fortrea Patient Access durch die Kombination mit dem tiefen Investitionssinn und der führenden operativen Branchenexpertise von Arsenal gut positioniert sind, um zu wachsen und den Patienten und Pharmasponsoren verbesserte Möglichkeiten zu bieten. Ich freue mich, dass wir auch weiterhin ein positiven Einfluss auf das Gesundheitswesen haben werden.“

„Endpoint und Fortrea Patient Access können auf eine stolze, jahrzehntelange Erfolgsgeschichte als Marktführer bei der Unterstützung der klinischen Forschung und der Vermarktung innovativer Therapien zurückblicken. Arsenal ist stolz darauf, Unternehmen aufzubauen, die das Gesundheitswesen auf sinnvolle Art verbessern. Wir freuen uns auf die Zusammenarbeit mit dem Management und den Mitarbeitern, um das Wachstum dieser beiden Unternehmen zu beschleunigen“, sagte Gene Gorbach, ein Investment Partner von Arsenal.

Dimitris Agrafiotis, Ph.D., Director of Digital, Analytics & AI bei Arsenal, sagte: „Endpoint und Fortrea Patient Access bieten unentbehrliche Lösungen, die die Teilnahme von Patienten an klinischen Studien und den Zugang zu Therapien ermöglichen. Ich freue mich, das talentierte Team von Endpoint und Fortrea Patient Access unterstützen zu können. Gemeinsam werden wir die technologischen Fähigkeiten weiter ausbauen, die das Engagement dieser Unternehmen für die Erbringung qualitativ hochwertiger Dienstleistungen für die pharmazeutische Industrie untermauern.“

Endpoint Clinical
Endpoint ist im wachstumsstarken eClinical–Markt als führender Anbieter von Randomisierungs– und Trial Supply Management (RTSM)–Lösungen für biopharmazeutische und CRO–Kunden tätig und verfügt über Fachwissen bei der Betreuung komplexer klinischer Studien im Spätstadium. Seit mehr als 15 Jahren kann Endpoint auf eine erfolgreiche Erfolgsbilanz bei der effektiven Unterstützung von mehr als 1.750 klinischen Studien mit 875.000 Patienten in 90 Ländern verweisen, hat zudem einen erstklassigen Kundenstamm aufgebaut und langjährige strategische Beziehungen gepflegt.

Fortrea Patient Access
Fortrea Patient Access ist führend auf dem Markt für HUB–Dienstleistungen und Patientenzugang und bietet der biopharmazeutischen Industrie seit mehr als 30 Jahren umfassende Lösungen für Patientenbetreuung, Produktzugang, Erschwinglichkeit und Adhärenz. Durch die kürzlich erweiterte nicht–kommerzielle Spezialapotheke FortreaRx™, die einen verbesserten Vertrieb von Kühlketten– und Ambient–Free–Goods–Produkten ermöglicht, ist Fortrea Patient Access bestrebt, die Ergebnisse für Patienten zu verbessern und die Zugänglichkeit zur Gesundheitsversorgung durch seine umfangreiche Erfahrung zu erhöhen, während es derzeit mehr als 2,5 Millionen Patienten und über 100 einzigartige Marken für mehr als 25 Krankheitsindikationen unterstützt.

Arsenal Capital Partners
Arsenal Capital Partners ist eine führende Private–Equity–Investmentgesellschaft, die sich auf den Aufbau marktführender Wachstums– und Gesundheitsunternehmen spezialisiert hat. Seit seiner Gründung im Jahr 2000 hat Arsenal institutionelle Beteiligungsfonds in Höhe von insgesamt über 10 Milliarden US–Dollar eingeworben, mehr als 290 Plattform– und Add–on–Akquisitionen abgeschlossen und mehr als 35 Realisierungen erzielt. Die Gesellschaft arbeitet mit Managementteams zusammen, um strategisch wichtige Unternehmen mit führenden Marktpositionen, hohem Wachstum und hoher Wertschöpfung aufzubauen. Weitere Informationen finden Sie unter www.arsenalcapital.com.

Berater
Barclays fungiert als exklusiver Finanzberater für Fortrea und Smith Anderson fungiert als Rechtsberater. Sidley Austin LLP fungierte als Rechtsberater für Arsenal.

Telefonkonferenz und Aufzeichnung zu den Ergebnissen
Fortrea wird die Ankündigung der Veräußerung in der Telefonkonferenz für das vierte Quartal 2023 erörtern, die heute um 9:00 Uhr ET stattfinden wird. Die Konferenz ist zugänglich über die Website für Investor Relations von Fortrea oder den folgenden Link zum Ergebnis–Webcast. Um Verzögerungen zu vermeiden, sollten Sie sich mindestens 10 Minuten vor Beginn der Telefonkonferenz anmelden. Eine Aufzeichnung der Live–Telefonkonferenz wird kurz nach Beendigung der Veranstaltung im Abschnitt Events & Presentations (Veranstaltungen und Präsentationen) auf der Website von Fortrea zur Verfügung stehen. Auf der Website für Investor Relations von Fortrea wird vor dem Beginn der Telefonkonferenz ebenfalls eine ergänzende Folienpräsentation zur Verfügung gestellt.

Über Fortrea
Fortrea (Nasdaq: FTRE) ist ein weltweit führender Anbieter von Lösungen für die klinische Entwicklung und den Zugang zu Patienten in der Biowissenschaftsbranche. Wir arbeiten mit aufstrebenden und großen biopharmazeutischen, biotechnologischen, medizintechnischen und diagnostischen Unternehmen zusammen, um Innovationen im Gesundheitswesen voranzutreiben, die das Angebot lebensverändernder Therapien für Patienten beschleunigen. Fortrea bietet Management von klinischen Studien der Phasen I–IV, klinische Pharmakologie, Beratungsdienstleistungen, differenzierte technologiegestützte Studienlösungen und Dienstleistungen nach der Zulassung. Die Lösungen von Fortrea basieren auf drei Jahrzehnten Erfahrung in mehr als 20 Therapiegebieten, einer Leidenschaft für wissenschaftliche Strenge, außergewöhnlichen Erkenntnissen und einem starken Netzwerk von Prüfzentren. Unser talentiertes und vielseitiges Team von etwa 18.000 Mitarbeitern in über 90 Ländern ist so skaliert, dass wir unseren Kunden weltweit gezielte und flexible Lösungen anbieten können. Erfahren Sie mehr darüber, wie Fortrea zu einer transformativen Kraft von der Pipeline bis zum Patienten wird, unter Fortrea.com und folgen Sie uns auf LinkedIn und X (früher Twitter) @Fortrea.

Warnhinweis zu zukunftsgerichteten Aussagen

Diese Pressemitteilung enthält „zukunftsgerichtete Aussagen“ im Sinne der US–Bundeswertpapiergesetze, einschließlich Abschnitt 27A des Securities Act und Abschnitt 21E des Exchange Act. Zukunftsgerichtete Aussagen beziehen sich naturgemäß auf Sachverhalte, die in unterschiedlichem Ausmaß ungewiss sind, wie beispielsweise Aussagen über die erwarteten Vorteile der Transaktion, einschließlich zukünftiger finanzieller und betrieblicher Leistungen, und den voraussichtlichen Zeitpunkt des Abschlusses der Transaktion. In diesem Zusammenhang beziehen sich zukunftsgerichtete Aussagen häufig auf die erwartete künftige Geschäfts– und Finanzentwicklung und die Finanzlage. Sie enthalten oft Begriffe wie „Prognose“, „erwarten“, „annehmen“, „vorhersehen“, „beabsichtigen“, „planen“, „voraussagen“, „glauben“, „anstreben“, „sehen“, „werden“, „würden“, „abzielen“ sowie ähnliche Ausdrücke und Variationen oder Verneinungen dieser Begriffe, die dazu dienen, zukunftsgerichtete Aussagen zu identifizieren, obwohl nicht alle zukunftsgerichteten Aussagen diese identifizierenden Wörter enthalten. Die tatsächlichen Ergebnisse können aufgrund einer Reihe von Faktoren erheblich von diesen zukunftsgerichteten Aussagen abweichen, einschließlich, aber nicht beschränkt auf: Erfüllung der aufschiebenden Bedingungen für den Vollzug der geplanten Veräußerung der Geschäftsbereiche Endpoint Clinical und Fortrea Patient Access, einschließlich der Fähigkeit, behördliche Genehmigungen zu erhalten, und der Fähigkeit des Unternehmens, die Transaktion rechtzeitig oder überhaupt abzuschließen; die Möglichkeit, dass der Abschluss der Transaktion teurer wird als erwartet, auch aufgrund unerwarteter Faktoren oder Ereignisse; die Fähigkeit der Parteien, die Erwartungen hinsichtlich der buchhalterischen und steuerlichen Behandlung der geplanten Transaktion zu erfüllen; und andere Faktoren, die von Zeit zu Zeit in Dokumenten beschrieben werden, die das Unternehmen bei der SEC einreicht. Eine weitere Erörterung der Risiken im Zusammenhang mit der Geschäftstätigkeit des Unternehmens finden Sie im Abschnitt „Risk Factors“ der Registrierungserklärung des Unternehmens auf Formular 10, die bei der Securities and Exchange Commission („SEC“) eingereicht wurde. Diese Faktoren können von Zeit zu Zeit in den nachfolgenden periodischen und anderen Einreichungen des Unternehmens bei der SEC geändert oder aktualisiert werden, die auf der Website der SEC unter www.sec.gov abrufbar sind. Diese Faktoren erheben keinen Anspruch auf Vollständigkeit und sollten in Verbindung mit den anderen Warnhinweisen gelesen werden, die in diesem Bericht und in den vom Unternehmen bei der SEC eingereichten Unterlagen enthalten oder durch Verweis einbezogen sind. Alle zukunftsgerichteten Aussagen beziehen sich nur auf das Datum der Veröffentlichung dieses Berichts, und das Unternehmen übernimmt keine Verpflichtung, zukunftsgerichtete Aussagen zu aktualisieren oder zu überarbeiten, um zukünftige Ereignisse oder Entwicklungen zu berücksichtigen, sofern dies nicht gesetzlich vorgeschrieben ist.

Kontakt zu Fortrea:
Hima Inguva (Investoren) – 877–495–0816, hima.inguva@fortrea.com
Sue Zaranek (Medien) – 919–943–5422, media@fortrea.com
Kate Dillon (Medien) – 646–818–9115, kdillon@prosek.com

Kontakt zu Arsenal:
Jackie Schofield unter pro–Arsenal@prosek.com


GLOBENEWSWIRE (Distribution ID 9062251)

]]>
Fortrea signe un accord définitif pour céder les activités Endpoint Clinical et Patient Access à Arsenal Capital Partners http://www.kuwaitfinancialexpress.com/?p=309913/ Tue, 12 Mar 2024 16:18:02 +0000 http://www.kuwaitfinancialexpress.com/?p=309913 Le projet de cession des activités Endpoint Clinical et Fortrea Patient Access permet à Fortrea de se recentrer sur son cœur de métier stratégique d’organisme de recherche contractuelle

Création de solutions autonomes de premier ordre pour la randomisation, la gestion de l’approvisionnement des essais et l’accès des patients, positionnées pour la différenciation et la croissance

DURHAM, État de Caroline du Nord, 12 mars 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq : FTRE) (la « Société »), un organisme de recherche sous contrat (« ORC ») de premier plan au niveau mondial, a annoncé aujourd’hui la signature d’un accord définitif de cession des actifs liés à son segment Enabling Services, à savoir ses activités Endpoint Clinical (ci–après « Endpoint ») et Fortrea Patient Access, à Arsenal Capital Partners (« Arsenal »), une société de capital–investissement de premier plan spécialisée dans la création d’entreprises de soins de santé leaders sur le marché et à fort profil technologique.

En cédant ces activités, Fortrea vise à faire progresser la stratégie de croissance et les solutions Endpoint et Fortrea Patient Access, en les positionnant de sorte à attirer davantage d’investissements afin d’accélérer la feuille de route technologique et d’améliorer encore les opérations pour soutenir les meilleures solutions et prestations pour les clients. Les activités restantes de Fortrea se concentreront davantage sur les phases de développement clinique 1 à 4. La conclusion de la transaction est prévue pour le deuxième trimestre 2024, sous réserve des conditions de finalisation habituelles et des approbations réglementaires, ainsi que de la conclusion par les parties de certains accords de services et d’exploitation.

« Ce jour marque une étape importante dans l’histoire de Fortrea, à l’heure où nous renforçons nos efforts en vue de croître organiquement comme un ORC à part entière, avec une bien plus grande souplesse financière », a déclaré Tom Pike, président–directeur général de Fortrea. « Après avoir procédé à un examen stratégique de nos activités, la cession d’Endpoint et de Fortrea Patient Access est conforme aux intérêts de nos clients. Arsenal a une grande expérience dans la création d’entreprises qui améliorent systématiquement les résultats en matière de santé, et je suis convaincu qu’Endpoint et Fortrea Patient Access seront en mesure de renforcer leur position sur le marché, de faire s’épanouir et grandir des talents de premier plan et d’investir dans de nouvelles capacités et ressources, tout en proposant des solutions qui améliorent la vie des patients. »

« Je me réjouis de ce nouveau chapitre qui s’écrit pour Endpoint et Fortrea Patient Access », a déclaré Sam Osman, président d’Enabling Services chez Fortrea, qui occupera le poste de PDG de ces entreprises avec Arsenal. « Ces entreprises seront particulièrement bien placées pour gérer efficacement le parcours du patient tout au long de la durée des essais cliniques, et ce, jusqu’à la commercialisation, en favorisant l’accès et l’adhésion des patients aux thérapies approuvées. En combinant les connaissances approfondies d’Arsenal en matière d’investissement et l’expertise opérationnelle du secteur, je suis convaincu que les activités d’Endpoint et de Fortrea Patient Access sont bien positionnées pour la croissance et la fourniture de capacités augmentées pour les patients et les promoteurs pharmaceutiques. Je me réjouis de l’impact positif que nous continuerons à avoir sur les soins de santé. »

« Endpoint et Fortrea Patient Access sont fiers de leur palmarès de plusieurs décennies en matière de leader sur le marché dans le soutien à la recherche clinique et à la commercialisation de thérapies innovantes. Arsenal est fier de créer des organisations qui améliorent de manière significative les soins de santé. Nous sommes ravis de nous associer à la direction et aux employés pour accélérer la croissance de ces deux entreprises », a déclaré Gene Gorbach, associé investisseur d’Arsenal.

Dimitris Agrafiotis, titulaire d’un doctorat, directeur du numérique, de l’analytique et de l’IA chez Arsenal, a déclaré : « Endpoint et Fortrea Patient Access fournissent des solutions essentielles qui permettent la participation des patients aux essais cliniques et l’accès aux thérapies. Je suis ravi de soutenir la talentueuse équipe d’Endpoint et de Fortrea Patient Access. Ensemble, nous allons encore améliorer la sophistication des capacités technologiques qui sous–tendent l’engagement de ces entreprises à fournir des services de la plus haute qualité à l’industrie pharmaceutique. »

Endpoint Clinical
Endpoint Clinical opère sur le marché à forte croissance de l’« eClinique » en tant que fournisseur de premier plan de solutions de randomisation et de gestion de l’approvisionnement des essais (« RTSM ») pour les clients biopharmaceutiques et les ORC, avec une expertise dans les essais cliniques complexes et en phase avancée de développement. Depuis plus de 15 ans, Endpoint a réussi à soutenir efficacement plus de 1 750 essais cliniques impliquant 875 000 patients dans 90 pays, à cultiver une clientèle de premier ordre et à entretenir des relations stratégiques de longue date.

Fortrea Patient Access
Fortrea Patient Access est un leader du marché des services HUB et de l’accès aux patients. Depuis plus de 30 ans, il propose à l’industrie biopharmaceutique des solutions complètes en matière de soutien aux patients, d’accès aux produits, d’accessibilité financière et d’observance. En outre, grâce à l’expansion récente de sa pharmacie spécialisée non commerciale, FortreaRx™, destinée à soutenir une distribution accrue des produits de la chaîne du froid et des produits gratuits à température ambiante, Fortrea Patient Access s’est engagée à améliorer les résultats pour les patients ainsi que l’accessibilité aux soins de santé, tout en soutenant actuellement plus de 2,5 millions de patients à travers plus de 100 marques uniques pour plus de 25 indications thérapeutiques.

Arsenal Capital Partners
Arsenal Capital Partners est une société de capital d’investissement privée de premier plan qui se spécialise dans la création d’entreprises industrielles de croissance et de soins de santé leaders sur le marché. Depuis sa création en 2000, Arsenal a levé des fonds d’investissement institutionnels d’un montant total de plus de 10 milliards de dollars, réalisé plus de 290 acquisitions de plateformes et d’actifs complémentaires, et plus de 35 cessions. La société travaille avec des équipes de gestion pour créer des entreprises d’importance stratégique avec des positions de leader sur le marché, une croissance élevée et une forte valeur ajoutée. Pour plus d’informations, rendez–vous sur www.arsenalcapital.com.

Conseillers
Barclays intervient en qualité de conseiller financier exclusif de Fortrea, et Smith Anderson comme son conseiller juridique. Sidley Austin LLP est intervenu en qualité de conseiller juridique d’Arsenal.

Conférence téléphonique de présentation des résultats et rediffusion
Fortrea discutera de l’annonce de la cession lors de sa conférence téléphonique sur les résultats du quatrième trimestre 2023, qui se tiendra aujourd’hui à 9 h, heure de l’Est. La conférence est accessible via le site Web des relations avec les investisseurs de Fortrea ou sur le lien redirigeant vers la webdiffusion des résultats. Pour éviter tout retard, veuillez vous inscrire au moins 10 minutes avant le début de l’appel. Une rediffusion de la conférence téléphonique en direct sera disponible peu après la fin de l’événement et accessible sur le site web de la Commission européenne, événements et présentations du site web de Fortrea U Un diaporama complémentaire sera également disponible sur le site Web des relations avec les investisseurs de Fortrea avant le début de la conférence téléphonique.

À propos de Fortrea
Fortrea (Nasdaq : FTRE) est l’un des principaux fournisseurs mondiaux de solutions de développement clinique et d’accès aux soins pour les patients dans le secteur des sciences de la vie. Fortrea s’associe à des sociétés établies et émergentes du domaine biopharmaceutique, de la biotechnologie des dispositifs médicaux et des diagnostics pour stimuler l’innovation en matière de santé, et accélérer la mise au point de traitements révolutionnaires pour les patients. Nous proposons des services de gestion d’essais cliniques de phase I à IV, de pharmacologie clinique, de services de consulting, d’essais différenciés axés sur des technologies habilitantes, et des services post–autorisation. Nos solutions s’appuient sur 30 ans d’expérience dans 20 domaines thérapeutiques, une passion pour la rigueur scientifique, des connaissances exceptionnelles et un solide réseau de centres de recherche. Notre équipe talentueuse et diversifiée d’environ 18 000 collaborateurs répartis sur plus de 90 pays est dimensionnée pour fournir des solutions ciblées et agiles à nos clients, partout dans le monde. Pour en savoir plus sur la manière dont Fortrea est un moteur d’influence du pipeline au patient, rendez–vous sur Fortrea.com et suivez–nous sur LinkedIn et X (anciennement Twitter) @Fortrea.

Mise en garde concernant les déclarations prospectives

Le présent communiqué de presse contient des « déclarations prospectives » au sens des lois fédérales sur les valeurs mobilières, notamment la Section 27A du Securities Act (la loi américaine sur les valeurs mobilières) et la Section 21E de l’Exchange Act (la loi américaine sur les Bourses de valeurs). Les déclarations prospectives traitent par nature de questions qui sont, à des degrés divers, incertaines, telles que les déclarations sur les avantages attendus de la transaction, y compris les performances financières et opérationnelles futures, ainsi que le calendrier prévu pour l’achèvement de la transaction. Dans ce contexte, les déclarations prospectives traitent souvent des performances commerciales et financières futures attendues et de la situation financière, et contiennent fréquemment des termes tels que « orientation », « s’attendre à », « supposer », « anticiper », « avoir l’intention », « planifier », « prévoir », « croire », « viser », « sera », « serait », « cible », des expressions similaires, ainsi que des variantes ou la forme négative de ces termes qui sont destinés à identifier les déclarations prospectives, bien que toutes les déclarations prospectives ne contiennent pas ces mots d’identification. Les résultats réels pourraient sensiblement différer de ces déclarations prospectives en raison d’un certain nombre de facteurs, y compris, mais sans s’y limiter : la satisfaction des conditions préalables à la réalisation de la transaction proposée pour la cession des activités Endpoint Clinical et Fortrea Patient Access, y compris la capacité à obtenir les autorisations réglementaires, ainsi que la capacité de la Société à réaliser la transaction dans les délais impartis ou à la réaliser en soi, la possibilité que la transaction soit plus coûteuse à réaliser que prévu, y compris en raison de facteurs ou d’événements inattendus, la capacité des parties à répondre aux attentes concernant les traitements comptables et fiscaux de la transaction proposée et d’autres facteurs décrits en tant que de besoin dans les documents que la Société dépose auprès de la Securities and Exchange Commission (« SEC »). Pour une analyse plus approfondie des risques liés à l’activité de la Société, voir la section « Facteurs de risque » de la Déclaration d’enregistrement de la Société sur le Formulaire 10, telle qu’elle a été déposée auprès de la SEC, ces facteurs pouvant être modifiés ou mis à jour en tant que de besoin dans les dépôts périodiques et autres de la Société introduits auprès de la SEC, qui sont accessibles sur le site Web de la SEC à l’adresse suivante : www.sec.gov. Ces facteurs ne doivent pas être considérés comme exhaustifs et doivent être lus conjointement avec les autres avertissements inclus ou incorporés par référence dans ce rapport et dans les documents déposés par la Société auprès de la SEC. Toutes les déclarations prospectives sont faites uniquement à la date du présent rapport et la Société ne s’engage pas, sauf si la loi l’exige, à mettre à jour ou à réviser les déclarations prospectives pour tenir compte d’événements ou de développements futurs.

Coordonnées de Fortrea :
Hima Inguva (Investisseurs) – 877–495–0816, hima.inguva@fortrea.com
Sue Zaranek (Médias) – 919–943–5422, media@fortrea.com
Kate Dillon (Médias) – 646–818–9115, kdillon@prosek.com

Contact Arsenal :
Jackie Schofield : pro–Arsenal@prosek.com


GLOBENEWSWIRE (Distribution ID 9062251)

]]>
Fortrea Assina Contrato Definitivo de Transferência das Unidades Endpoint Clinical e Patient Access para a Arsenal Capital Partners http://www.kuwaitfinancialexpress.com/?p=309909/ Tue, 12 Mar 2024 16:18:02 +0000 http://www.kuwaitfinancialexpress.com/?p=309909 A proposta da transferência das unidades Endpoint Clinical e Fortrea Patient Access agiliza ainda mais o foco estratégico da Fortrea como uma organização de pesquisa sob contrato

Ela cria as melhores soluções independentes de Randomização e Gestão de Fornecimento de Ensaios e Acesso do Paciente posicionadas para diferenciação e crescimento

DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) — A Fortrea (Nasdaq: FTRE) (a “Empresa”), uma organização líder global de pesquisa por contrato (CRO), anunciou hoje que assinou um contrato definitivo de transferência dos ativos relacionados ao seu segmento Enabling Services, ou seja, suas unidades Endpoint Clinical (“Endpoint”) e Fortrea Patient Access, para a Arsenal Capital Partners (“Arsenal”), uma empresa líder de private equity especializada na criação de empresas de saúde líderes de mercado e ricas em tecnologia.

Com a transferência dessas unidades, a Fortrea visa promover a estratégia de crescimento e soluções da Endpoint e da Fortrea Patient Access, posicionando–as para aumentar o investimento para acelerar o roteiro de tecnologia e aprimorar ainda mais as operações para apoiar as melhores soluções e entregas aos clientes. As outras unidades da Fortrea irão fortalecer seu foco nas fases de desenvolvimento clínico 1 a 4. A conclusão da transação está prevista para o segundo trimestre de 2024, estando sujeita às condições habituais de fechamento e aprovações regulatórias, bem como às partes que celebram certos serviços e contratos operacionais.

“Hoje é um marco significativo na jornada contínua da Fortrea, à medida que aprimoramos nosso foco em crescer organicamente como uma CRO pura, com flexibilidade financeira adicional”, disse o presidente e CEO da Fortrea, Tom Pike. “Depois de uma revisão estratégica de nossos negócios, concluímos que a transferência das unidades Endpoint e Fortrea Patient Access se alinha aos interesses dos nossos clientes. A Arsenal tem uma vasta experiência na criação de empresas que criam melhorias sistemáticas nos resultados de saúde, e estou confiante de que a Endpoint e a Fortrea Patient Access poderão fortalecer suas posições no mercado, cultivar talentos de primeira linha e investir em novas capacidades e recursos, ao mesmo tempo, oferecer soluções que melhoram a vida dos pacientes.”

“Estou muito entusiasmado com este próximo capítulo da Endpoint e a Fortrea Patient Access”, disse Sam Osman, presidente da Enabling Services da Fortrea, que atuará como CEO dessas empresas com a Arsenal. “Essas empresas estarão distintamente posicionadas para gerenciar efetivamente a jornada do paciente nos ensaios clínicos e na comercialização, impulsionando o acesso e a adesão do paciente às terapias aprovadas. Com a união da profunda perspicácia de investimento da Arsenal com a experiência operacional líder do setor, estou confiante de que as empresas Endpoint e Fortrea Patient Access estão bem posicionadas para o crescimento e a entrega de recursos aprimorados para pacientes e patrocinadores farmacêuticos. Quero dar continuidade ao impacto positivo no cuidado da saúde.”

“A Endpoint e a Fortrea Patient Access têm um histórico orgulhoso de décadas de liderança no mercado no apoio à pesquisa clínica e comercialização de terapias inovadoras. A Arsenal tem orgulho em criar organizações que melhoram significativamente os cuidados da saúde. Estamos entusiasmados com a parceria com a administração e os funcionários para acelerar o crescimento desses dois negócios”, disse Gene Gorbach, um Parceiro de Investimento da Arsenal.

Dimitris Agrafiotis, Ph.D., Diretor de Digital, Análise e IA da Arsenal, disse: “A Endpoint e a Fortrea Patient Access fornecem soluções essenciais que permitem a participação dos pacientes em ensaios clínicos e acesso a terapias. Tenho o prazer de apoiar a equipe talentosa da Endpoint e da Fortrea Patient Access. Juntos, aumentaremos ainda mais a sofisticação das capacidades tecnológicas que sustentam o compromisso dessas empresas em fornecer serviços da mais alta qualidade para a indústria farmacêutica.”

Endpoint Clinical
A Endpoint opera no mercado eClinical de alto crescimento como provedora líder de soluções de Randomização e Gerenciamento de Fornecimento de Ensaios (RTSM) para clientes biofarmacêuticos e CRO, com experiência no atendimento de ensaios clínicos complexos e em estágio avançado. Com mais de 15 anos, a Endpoint já apoiou com sucesso mais de 1.750 ensaios clínicos envolvendo 875.000 pacientes em 90 países e cultivou uma base de clientes de primeira linha e relacionamentos estratégicos de longa data.

Fortrea Patient Access
A Fortrea Patient Access é uma líder em escala no mercado de serviços de HUB e acesso do paciente, atendendo à indústria biofarmacêutica com suporte abrangente ao paciente, acesso ao produto, acessibilidade e soluções de adesão há mais de 30 anos. Avançando ainda mais com sua especializada farmácia não comercial recentemente expandida, a FortreaRx™, para apoiar a distribuição aprimorada de produtos de cadeia fria e sem ambiente, a Fortrea Patient Access está comprometida em impulsionar os resultados dos pacientes e aprimorar a acessibilidade aos cuidados da saúde por meio da sua ampla experiência, oferecendo suporte a mais de 2,5 milhões de pacientes e mais de 100 marcas exclusivas para mais de 25 indicações de doenças.

Arsenal Capital Partners
A Arsenal Capital Partners é uma empresa líder em investimentos em patrimônio privado especializada na criação de empresas líderes de mercado em crescimento industrial e saúde. Desde a sua criação em 2000, o Arsenal levantou fundos de investimento de capital institucional com um total de mais de US$ 10 bilhões, concluiu mais de 290 aquisições de plataformas e complementos, e alcançou mais de 35 realizações. A empresa trabalha com equipes de gestão para criar empresas estrategicamente importantes com posições de liderança no mercado, alto crescimento e alto valor agregado. Para mais informação, visite www.arsenalcapital.com.

Consultores
Barclays está atuando como consultor financeiro exclusivo da Fortrea, e Smith Anderson como consultor jurídico. A Sidley Austin LLP atuou como consultora jurídica da Arsenal.

Chamada e Replay de Ganhos
A Fortrea discutirá o anúncio da transferência na sua teleconferência de resultados do quarto trimestre de 2023, que será realizada hoje às 9h ET. A conferência pode ser acessada no site Investor Relations da Fortrea (Relacionamento com o Investidor) ou no seguinte link earnings webcast (Webcast de ganhos). Para evitar possíveis atrasos, acesse pelo menos 10 minutos antes do início da chamada. Um replay da teleconferência ao vivo estará disponível logo após a conclusão do evento e acessível na seção events and presentationts (eventos e apresentações) do site da Fortrea. Uma apresentação de slides suplementar também estará disponível no site Investor Relations da Fortrea antes do início da chamada.

Sobre a Fortrea
A Fortrea (Nasdaq: FTRE) é fornecedora líder global de soluções para o desenvolvimento clínico e acesso ao paciente para a indústria de ciências da vida. Fazemos parcerias com grandes e emergentes empresas biofarmacêuticas, de biotecnologia, de dispositivos médicos e de diagnóstico para impulsionar a inovação na saúde que acelera terapias que mudam a vida dos pacientes. A Fortrea fornece gerenciamento de testes clínicos de fase I–IV, farmacologia clínica, serviços de consultoria, soluções de testes com tecnologia diferenciada e serviços pós–aprovação. As soluções da Fortrea utilizam suas três décadas de experiência abrangendo mais de 20 áreas terapêuticas, sua dedicação ao rigor científico, insights excepcionais e uma forte rede de pesquisadores. Nossa equipe talentosa e diversificada de aproximadamente 18.000 pessoas que trabalham em mais de 90 países é dimensionada para fornecer soluções focadas e ágeis para clientes de todo o mundo. Saiba mais sobre como a Fortrea está se tornando uma força transformadora de pipeline para paciente na Fortrea.com e siga–nos no LinkedIn e X (antigo Twitter) @Fortrea.

Advertência a Respeito de Declarações de Previsão

Este comunicado contém “declarações de previsão” de acordo com a definição do termo estabelecido na Seção 27A da Lei de Valores Mobiliários (Securities Act) e na Seção 21E da Lei de Mercados Mobiliários (Securities Exchange Act). As declarações de previsão, por sua natureza, abordam questões que são, em diferentes graus, incertas, como as declarações sobre os benefícios previstos da transação, incluindo o desempenho financeiro e operacional futuro, e o prazo previsto para a conclusão da transação. Neste contexto, as declarações de previsão geralmente abordam o desempenho futuro esperado e o desempenho financeiro e a condição financeira, e muitas vezes contêm palavras como “orientação”, “esperar”, “supor”, “antecipar”, “pretender”, “planejar”, “prever”, “acreditar”, “buscar”, “ver”, “irá”, “faria”, “alvo”, expressões semelhantes e variações ou negativos dessas palavras que se destinam a identificar declarações de previsão, embora nem todas as declarações de previsão contenham essas palavras de identificação. Os resultados reais podem diferir materialmente dessas declarações de previsão devido a uma série de fatores, incluindo, mas não se limitando a: satisfação das condições precedentes à consumação da transferência proposta da transação das unidades Endpoint Clinical e Fortrea Patient Access, incluindo a capacidade de garantir aprovações regulatórias e a capacidade da Empresa de concluir a transação em tempo hábil ou de alguma forma; a possibilidade de que a transação possa ser mais cara do que o previsto, inclusive como resultado de fatores ou eventos inesperados; a capacidade das partes de atender às expectativas em relação aos tratamentos contábeis e fiscais da transação proposta; e outros fatores descritos ocasionalmente nos documentos que a Empresa arquiva junto à SEC. Para uma discussão mais aprofundada dos riscos relacionados aos negócios da Empresa, consulte a Seção “Fatores de Risco” da Declaração de Registro da Empresa no Formulário 10, conforme arquivado na Comissão de Valores Mobiliários (a “SEC”), pois tais fatores podem ser alterados ou atualizados ocasionalmente nos registros periódicos e outros registros subsequentes da Empresa na SEC, acessíveis no site da SEC em www.sec.gov. Esses fatores não devem ser interpretados como exaustivos e devem ser lidos em conjunto com as outras declarações de advertência incluídas ou incorporadas por referência neste relatório e nos registros da Empresa na SEC. As declarações de previsão incluídas neste comunicado são válidas apenas a partir da presente data e não assumimos nenhuma obrigação de atualizar essas declarações de previsão para indicar eventos ou acontecimentos subsequentes.

Contatos da Fortrea:
Hima Inguva (Investidores) – 877–495–0816, hima.inguva@fortrea.com
Sue Zaranek (Mídia) – 919–943–5422, media@fortrea.com
Kate Dillon (Mídia) – 646–818–9115, kdillon@prosek.com

Contato da Arsenal:
Jackie Schofield, pro–Arsenal@prosek.com


GLOBENEWSWIRE (Distribution ID 9062251)

]]>
Fortrea Signs Definitive Agreement to Divest Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners http://www.kuwaitfinancialexpress.com/?p=309907/ Mon, 11 Mar 2024 10:30:00 +0000 http://www.kuwaitfinancialexpress.com/?p=309907 Proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses further streamlines Fortrea’s strategic focus as a pure–play contract research organization

Creates standalone best–in–class Randomization and Trial Supply Management and Patient Access solutions positioned for differentiation and growth

DURHAM, N.C., March 11, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has signed a definitive agreement to divest assets relating to its Enabling Services segment, namely its Endpoint Clinical (“Endpoint”) and Fortrea Patient Access businesses, to Arsenal Capital Partners (“Arsenal”), a leading private equity firm specializing in building market–leading, technology–rich healthcare companies.

By divesting these businesses, Fortrea aims to advance the growth strategy and solutions of Endpoint and Fortrea Patient Access, positioning them for increased investment to accelerate the technology roadmap and further enhance operations to support best–in–class customer solutions and delivery. The remaining business of Fortrea will strengthen its focus on clinical development phases 1 through 4. Closing is targeted for the second quarter of 2024, subject to customary closing conditions and regulatory approvals, as well as the parties entering into certain services and operating agreements.   

“Today marks a significant milestone in Fortrea’s ongoing journey, as we sharpen our focus on organically growing as a pure–play CRO, with added financial flexibility,” said Fortrea Chairman and CEO Tom Pike. “After undertaking a strategic review of our business, divesting Endpoint and Fortrea Patient Access aligns with the interests of our customers. Arsenal has extensive experience in building businesses that create systematic improvement in health outcomes, and I am confident that Endpoint and Fortrea Patient Access will be able to strengthen their market positions, nurture top–tier talent and invest in new capabilities and resources while delivering solutions that improve patients’ lives.”

“I am excited for this next chapter for Endpoint and Fortrea Patient Access,” said Sam Osman, president of Enabling Services at Fortrea, who will serve as the CEO of these businesses with Arsenal. “These businesses will be distinctively positioned to effectively manage the patient journey across clinical trials and into commercialization by driving patient access and adherence for approved therapies. Combining Arsenal’s deep investment acumen and leading industry operational expertise, I am confident the Endpoint and Fortrea Patient Access businesses are well positioned for growth and delivery of enhanced capabilities for patients and pharma sponsors. I look forward to our continued positive impact on healthcare.”

“Endpoint and Fortrea Patient Access have a proud, decades–long track record of market leadership in supporting clinical research and commercialization of innovative therapies. Arsenal takes pride in building organizations that meaningfully improve healthcare. We are excited to partner with management and employees to accelerate the growth of these two businesses,” said Gene Gorbach, an Investment Partner of Arsenal.

Dimitris Agrafiotis, Ph.D., Director of Digital, Analytics & AI at Arsenal said, “Endpoint and Fortrea Patient Access provide essential solutions that enable patients’ participation in clinical trials and access to therapies. I am delighted to support the talented team at Endpoint and Fortrea Patient Access. Together, we will further enhance the sophistication of technology capabilities that underpin these companies’ commitment to delivering the highest quality services to the pharmaceutical industry.”

Endpoint Clinical
Endpoint operates in the high growth eClinical market as a leading provider of Randomization and Trial Supply Management (RTSM) solutions to biopharmaceutical and CRO customers with expertise in serving complex and late–stage clinical trials. For more than 15 years, Endpoint has had a successful track record of effectively supporting more than 1,750 clinical trials involving 875,000 patients across 90 countries and has cultivated a blue–chip customer base and nurtured long–standing strategic relationships.

Fortrea Patient Access
Fortrea Patient Access is a scaled leader in the HUB services and patient access market, serving the biopharmaceutical industry with comprehensive patient support, product access, affordability and adherence solutions for more than 30 years. Further advanced by its recently expanded non–commercial specialty pharmacy, FortreaRx™, to support enhanced distribution of cold–chain and ambient free goods products, Fortrea Patient Access is committed to driving patient outcomes and improving healthcare accessibility through its extensive experience while currently supporting more than 2.5 million patients and over 100 unique brands across more than 25 disease indications.

Arsenal Capital Partners
Arsenal Capital Partners is a leading private equity investment firm that specializes in building market–leading industrial growth and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds totaling over $10 billion, completed more than 290 platform and add–on acquisitions, and achieved more than 35 realizations. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value–add.  For more information, visit www.arsenalcapital.com.

Advisors
Barclays is serving as exclusive financial advisor to Fortrea, and Smith Anderson is serving as its legal counsel. Sidley Austin LLP served as Arsenal’s legal counsel.

Earnings Call and Replay
Fortrea will discuss the divestiture announcement on its fourth quarter 2023 earnings conference call, which will be held today at 9:00 am ET. The conference can be accessed through the Fortrea Investor Relations website or the following earnings webcast link. To avoid potential delays, please join at least 10 minutes prior to the start of the call. A replay of the live conference call will be available shortly after the conclusion of the event and accessible on the events and presentations section of the Fortrea website. A supplemental slide presentation will also be available on the Fortrea Investor Relations website prior to the start of the call.

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I–IV clinical trial management, clinical pharmacology, consulting services, differentiated technology–enabled trial solutions and post–approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of about 18,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Cautionary Statement Regarding Forward–Looking Statements

This press release contains “forward–looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward–looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the anticipated benefits of the transaction, including future financial and operating performance, and the anticipated timing for completing the transaction. In this context, forward–looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward–looking statements, although not all forward–looking statements contain these identifying words. Actual results could differ materially from these forward looking statements due to a number of factors, including, but not limited to: satisfaction of the conditions precedent to consummation of the proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses transaction, including the ability to secure regulatory approvals, and the Company’s ability to complete the transaction in a timely manner or at all; the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the parties’ ability to meet expectations regarding the accounting and tax treatments of the proposed transaction; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company’s business, see the “Risk Factors” Section of the Company’s Registration Statement on Form 10, as filed with the Securities and Exchange Commission (the “SEC”), as such factors may be amended or updated from time to time in the Company’s subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included or incorporated by reference in this report and in the Company’s filings with the SEC. All forward–looking statements are made only as of the date of this report and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward–looking statements to reflect future events or developments.

Fortrea Contacts:
Hima Inguva (Investors) – 877–495–0816, hima.inguva@fortrea.com
Sue Zaranek (Media) – 919–943–5422, media@fortrea.com
Kate Dillon (Media) – 646–818–9115, kdillon@prosek.com

Arsenal Contact:
Jackie Schofield at  pro–Arsenal@prosek.com


GLOBENEWSWIRE (Distribution ID 9061141)

]]>
Ceridian Becomes Dayforce http://www.kuwaitfinancialexpress.com/?p=309646/ Thu, 01 Feb 2024 12:00:00 +0000 http://www.kuwaitfinancialexpress.com/?p=309646 TORONTO and MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) —  Dayforce, Inc. (NYSE: DAY; TSX: DAY) (the “Company”), a global human capital management (HCM) leader that makes work life better, today announced its change in legal name and brand from Ceridian to Dayforce. Dayforce is the Company’s flagship HCM platform, which delivers value to thousands of organizations and millions of workers globally and has consistently been ranked as a market leader based on a rich history of innovation and excellence.

With this brand evolution, the Company continues to set a new standard for the HCM industry – one that is fueled by a commitment to help today’s boundless workforce become more engaged, empowered, efficient, and purposeful. This includes ongoing investment in simplicity at scale through AI–driven innovations and best–in–class experiences across every stage of the customer journey – helping organizations realize their full people potential, operate with confidence, and unlock quantifiable value.

“As one united brand – Dayforce – we firmly believe we can amplify our promise to make work life better,” said David Ossip, Chair and CEO, Dayforce, Inc. “Dayforce represents our products, company, and community at its best. As Dayforce, we will further our ability to foster the happiest customers, the most engaged employees, the best products, and the greatest return for the market.”

Ossip shares more in the blog: We are Dayforce, which can be found on the Company’s new website.

To learn more:

About Dayforce  
Dayforce makes work life better. Everything we do as a global leader in HCM technology is focused on improving work for thousands of customers and millions of employees around the world. Our single, global people platform for HR, payroll, talent, workforce management, and benefits equips Dayforce customers to unlock their full workforce potential and operate with confidence. To learn how Dayforce helps create quantifiable value for organizations of all sizes and industries, visit dayforce.com.   

Forward–Looking Statement
This press release contains forward–looking statements that involve a number of risks and uncertainties. Statements that are not historical facts, including statements regarding our legal name change, the benefits of our unified branding, our investments in AI–driven innovations and best–in–class experiences, and our expectations, hopes, intentions or strategies regarding the future are forward–looking statements. Forward–looking statements are based on management's beliefs, as well as assumptions made by, and information currently available to, management. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected. These forward–looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, we undertake no obligation to update any forward–looking statements, whether as a result of new information, future events, or otherwise.

This press release should be read in conjunction with the risks detailed in the “Cautionary Note Regarding Forward–Looking Information,” “Forward–Looking Statement”, “Risk Factors” and other sections of our Quarterly Reports on Form 10–Q, Annual Reports on Form 10–K and other reports we file with the Securities and Exchange Commission. Copies of reports filed with the Securities and Exchange Commission are posted on our website and are available from us without charge.

Media Contact
Teri Murphy
647–417–2117
Teri.Murphy@dayforce.com


GLOBENEWSWIRE (Distribution ID 9029887)

]]>
MGA Entertainment Establishes Four Subsidiaries to Support its Fast Growing International Business in the European Union http://www.kuwaitfinancialexpress.com/?p=309626/ Thu, 01 Feb 2024 08:15:00 +0000 http://www.kuwaitfinancialexpress.com/?p=309626 LOS ANGELES, Feb. 01, 2024 (GLOBE NEWSWIRE) — MGA Entertainment, Inc. (MGA), one of the largest and fastest growing privately held toy and entertainment companies in the world, announced today it has established four wholly–owned subsidiaries in the European Union (EU) to support its fast growing international business. The four subsidiaries – MGA Toys Iberia S.L. (led by Managing Director Mila Gonzalez), MGA Entertainment Greece (led by Managing Director Panos Kalogeropoulos), MGA Entertainment Italy SRL (led by Managing Director Andrea Signorelli), and MGA Toys France (led by Managing Director Thierry Thivolle) – will support marketing and sales administration efforts, staffed by employees who have worked for MGA Entertainment in each of the markets, now employees of their respective subsidiary in the same roles. This move demonstrates the company’s commitment to growing its businesses in those markets and to its international business overall. 

“Our business outside of the U.S is strong and increasingly important to MGA Entertainment. Establishing these new subsidiaries will allow us to grow our business more quickly in these important markets,” said MGA Entertainment Founder & CEO Isaac Larian. “I look forward to working closely with the teams in each of these markets to continue to bring new, innovative, and fun MGA toys and products to consumers across the EU.”  

MGA previously announced its plans to merge with Zapf Creation AG, Europe’s leading manufacturer of nurturing dolls. MGA’s wholly–owned German subsidiary has entered into negotiations of a merger agreement which is expected to close in late Spring 2024.

###

About MGA, Entertainment, Inc.
MGA Entertainmentis one of the largest and fastest growing privately held toy and entertainment companies in the world. Headquartered in Los Angeles with offices globally, the company creates innovative, proprietary, and licensed consumer products and entertainment properties, including toys, games, dolls, apparel, consumer electronics, home décor, stationery, sporting goods, movies, and television series. The MGA family includes award–winning brands such as L.O.L. Surprise!™Little Tikes®, Rainbow High™Bratz®MGA’s Miniverse™Fluffie Stuffiez™Na! Na! Na! Surprise™, Micro Games of America™, BABY born®, and Zapf Creation®. For more information, please visit us at www.mgae.com or check us out at LinkedIn, ThreadsInstagram and Facebook

Attachment


GLOBENEWSWIRE (Distribution ID 9030048)

]]>
The Coretec Group to Postpone its January 11 Shareholder Call to a Later Date http://www.kuwaitfinancialexpress.com/?p=309486/ Mon, 08 Jan 2024 16:22:54 +0000 http://www.kuwaitfinancialexpress.com/?p=309486 ANN ARBOR, Mich., Jan. 08, 2024 (GLOBE NEWSWIRE) — The Coretec Group (OTCQB: CRTG), developers of silicon anode active materials for lithium–ion batteries, and cyclohexasilane (CHS) for EV, cleantech, and 3D display technology, today announced it will postpone its planned January 11, 2024 shareholder call to a later date, as the Company seeks to finalize and incorporate details of new, promising corporate developments into the presentation.

The Coretec Group leadership appreciates the patience from investors and stakeholders and looks forward to sharing notable developments, including the latest news on the Endurion program, in the near future.

The Company will provide updated details regarding the rescheduled shareholder call later this month. In the interim, Coretec leadership encourages anyone interested in further updates to follow the Company’s profiles LinkedIn and X (formerly Twitter).

About The Coretec Group

The Coretec Group, Inc. is an Ann Arbor, Michigan–based developer of engineered silicon and is using its expertise to develop silicon anodes for lithium–ion batteries that will charge faster and last longer. This program is called Endurion. Silicon has the theoretical ability to hold up to 10x the amount of lithium–ions as compared to traditional graphite. Through its proprietary micron and nanoparticle approach, Endurion is loading silicon into the battery anode. A modest increase in silicon will be a game changer that will revolutionize the EV market as well as other energy storage applications.

Additionally, the Company is using its engineered silicon to develop a portfolio of other energy–focused products, including solid–state lighting (LEDs), semiconductors, and printable electronics. Coretec continues to develop CSpace, its 3D volumetric display technology with a wide array of applications including medical imaging, automotive, and others.

For more information, please visit thecoretecgroup.com.

Follow The Coretec Group on:

X (Formerly Twitter) – @CoretecGroupInc
LinkedIn – www.linkedin.com/company/24789881
YouTube – www.youtube.com/channel/UC1IA9C6PoPd1G4M7B9QiZPQ/featured

Forward–Looking Statements

The statements in this press release that relate to The Coretec Group’s expectations with regard to the future impact on the Company’s results from operations are forward–looking statements and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward–looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Corporate Contact:
The Coretec Group, Inc.
Lindsay McCarthy
info@thecoretecgroup.com
+1 (866) 916–0833

Media Contact:
Spencer Herrmann
FischTank PR
coretec@fischtankpr.com
+1 (518) 669–6818


GLOBENEWSWIRE (Distribution ID 9014247)

]]>
STX Group Launches Working Capital Solution to Accelerate Renewable Energy Transition http://www.kuwaitfinancialexpress.com/stx-group-launches-working-capital-solution-to-accelerate-renewable-energy-transition/ Tue, 05 Dec 2023 11:30:00 +0000 http://www.kuwaitfinancialexpress.com/?p=309261 Amsterdam, Dec. 05, 2023 (GLOBE NEWSWIRE) — AMSTERDAM (December 5, 2023) STX Group, a leading environmental markets and climate solutions firm, today announces the launch of a working capital solution, specifically designed for environmental certificates. The launch comes as a response to the increased requirements for companies to hold environmental certificates to meet their ESG targets. Traditional financing methods often fall short in providing the necessary funding. STX Group has established an independent Special Purpose Vehicle (SPV) offering companies the necessary working capital funding for their environmental certificates.

The new service provides STX Group's customers and counterparties with financial flexibility to manage the energy transition.

The newly launched SPV solution differs from traditional financing through the wide range of liquid and less liquid certificates that can be financed as well as offering higher advance rates. The SPV takes temporary ownership of the environmental commodities which may allow for balance sheet friendly treatment of the financing. The SPV is an attractive platform for lenders to gain access to one of the fastest growing parts of the credit universe. Through its extensive client base, STX Group has unrivaled access to counterparties looking to finance their environmental certificate holdings. This allows lenders to add collateralized credit exposure to highly rated counterparties to their portfolio.

The introduction of the SPV follows a sequence of new financial solutions and services introduced by STX Group earlier this year, placing the company at the forefront of incumbent financial markets where environmental commodities play an emerging role. This momentum is underscored by recent additions to STX Group's portfolio, including the April 2023 launch of the borrowing base facility where a broad base of environmental commodities was for the first time recognizes as collateral by global banks, and the unveiling of the STX Group carbon fund in October 2023. Both demonstrate the growing importance of environmental commodities as pivotal financial instruments.

"The launch of this new solution provides immense opportunities for our customers and counterparties as they increase their activities in environmental commodities markets. We are delighted to work with them by providing them with more efficient and secure market access," said Bart Wesselink, Chief Financial and Risk Officer of STX Group.

The SPV is independently managed by Vistra, one of the leading fund administrator and corporate service providers. Vistra is regulated by Dutch Central Bank DNB.

– ENDS –

About STX Group

STX Group is a leading global environmental commodity trader and climate solutions provider. For over 15 years, the company has been at the forefront of the global transition towards a low–carbon economy. By leveraging its expertise in accurately pricing pollution and emissions, it has helped to cultivate trust in market–based solutions to the decarbonization of the economy.

With its trading and Corporate Climate Solutions offerings, STX Group ensures that money flows to hundreds and thousands of projects that make the world a greener place, while providing corporations with the certified proof–points of their contributions to environmental progress.

After acquiring Vertis and its subsidiary Strive in December 2021, the STX Group now boasts a diverse team of nearly 500 employees from over 50 countries. Headquartered in Amsterdam, the Netherlands, STX Group has 13 offices around the world and an annual trading volume of over EUR 4 billion.

For more information, please visit https://stxgroup.com/

Note to editors "" not for publication

Media contact

Jaime Santisteban

media@stxgroup.com

+33 6 80 80 99 98

Attachment


GLOBENEWSWIRE (Distribution ID 8989794)

]]>
Gap Inc., Cargill, and GSK Join the Water Resilience Coalition and WaterAid to Improve Access to Water in India as Part of the Coalition's 2030 100-Basin Plan http://www.kuwaitfinancialexpress.com/gap-inc-cargill-and-gsk-join-the-water-resilience-coalition-and-wateraid-to-improve-access-to-water-in-india-as-part-of-the-coalitions-2030-100-basin-plan/ Tue, 17 Oct 2023 15:12:00 +0000 http://www.kuwaitfinancialexpress.com/?p=308785 New York, New York, Oct. 17, 2023 (GLOBE NEWSWIRE) — The Water Resilience Coalition (WRC), an industry–driven, CEO–led initiative convening global companies to address the global water crisis, today announced the launch of the Women + Water Collaborative, a flagship corporate collective action program to improve access to clean water and sanitation in India.

Gap Inc., Cargill, and GSK, in partnership with WaterAid and the Water Resilience Coalition, are launching the initiative to improve health, livelihoods, and climate resilience in water–stressed communities in India, beginning with the Krishna and Godavari basins. The WRC is an initiative of the CEO Water Mandate, a partnership between the UN Global Compact and the Pacific Institute.

This marks the first time that companies from different sectors spanning apparel, biopharma, and agriculture have united with shared goals, metrics, and governance to provide access to clean water and sanitation in the same communities. The Collaborative builds on the success of the previous USAID Gap Inc. Women + Water Alliance, which empowered over 2.4 million people to improve their access to water and sanitation in India between 2017 and 2023. This is one of 21 collective action projects in 15 basins underway across Asia, Africa, South America, and North America as part of the Water Resilience Coalition's 2030 ambition to build water resilience across 100 Priority Basins.

The Women + Water Collaborative will improve the availability and quality of water in priority river basins through water replenishment and conservation using methods such as rainwater harvesting. It will provide communities with safe drinking water and climate–resilient sanitation and hygiene infrastructure and services. Although women in rural India play a crucial role in water collection and use, their participation in decision–making around water resources remains low. This program will leverage women's leadership to build water resilience, improve water security, and enable equitable access to water and sanitation for communities at scale.

“As part of the Forward Faster Water Resilience Target and as members of the Water Resilience Coalition, the companies involved in this initiative have joined an alliance that thrives on collaboration and collective action. This cooperation will play a key role in achieving the WRC's ambitious goals outlined in its 2030 strategy,” said Sanda Ojiambo, CEO and Executive Director of the United Nations Global Compact and Co–Chair of the Water Resilience Coalition.

“The Women + Water Collaborative builds on Gap Inc.'s history of designing innovative programs with nonprofits and the public sector, and then convening corporate partners to drive sustainability at scale," said Dan Fibiger, Head of Global Sustainability for Gap Inc. "By joining across food, fashion and biopharma, we can drive meaningful impact in communities that fuel our global supply chains."

"Water is essential for human health, as well as for the ongoing production of our medicines and vaccines," said Claire Lund, VP Sustainability at GSK. "Yet climate change and nature loss are impacting water and health in locally specific ways "" with some countries being more vulnerable. That's why we are focused on water as part of our commitment to contributing to a nature positive world. We are proud to be a founding partner of the Women + Water Collaborative to improve water quality, quantity, and access in India, in turn helping to support local community health."

This flagship collective action program demonstrates tangible progress toward the Water Resilience Coalition's ambition to contribute to water security for 3 billion people and enable equitable access to water, sanitation, and hygiene for more than 300 million people by 2030.

"We know that reliable access to clean water and sanitation is essential for people and agriculture. At Cargill, we are focused on improving access to safe drinking water and sanitation, with the goal of reaching 500,000 people in priority communities by 2030," said Michelle Grogg, Vice President of Corporate Responsibility at Cargill. "Partnership and collective action are a critical pathway to help us deliver on this ambition and we're pleased to be a participating company in the Women + Water Collaborative."

WaterAid will launch the program in five Indian states and six priority districts. The NGO is keen to bring on additional corporate partners to expand the reach.

"Our impact is limited only by the number of corporate partners we are able to bring on," says Kelly Parsons, CEO of WaterAid America. "We know that solving the water crisis is a business imperative. We also know that none of the sustainable development goals will be achieved without global collaboration and partnership. By coordinating large, multi–stakeholder partnerships, we create holistic impact, at scale. That's the power of collective action.”

##

About the Water Resilience Coalition

The Water Resilience Coalition is an industry–driven, CEO–led initiative of the CEO Water Mandate that aims to elevate the long–term mounting crisis of global water stress to the top of the corporate agenda and to preserve the world's freshwater resources through collective action in water–stressed basins and ambitious, quantifiable commitments. Since the Coalition's launch in 2020, 35 global companies across multiple sectors with a combined market cap of US$4.8 trillion and operations in more than 140 countries have joined the effort. For more information, visit ceowatermandate.org/resilience.

About the Pacific Institute

Founded in 1987, the Pacific Institute is a global water think tank that combines science–based thought leadership with active outreach to influence local, national, and international efforts in developing sustainable water policies. From working with Fortune 500 companies to frontline communities, our mission is to create and advance solutions to the world's most pressing water challenges. Since 2009, the Pacific Institute has also acted as co–secretariat for the CEO Water Mandate, a global commitment platform that mobilizes a critical mass of business leaders to address global water challenges through corporate water stewardship. For more information, visit pacinst.org.

About the UN Global Compact

As a special initiative of the United Nations Secretary–General, the UN Global Compact is a call to companies worldwide to align their operations and strategies with Ten Principles in the areas of human rights, labour, environment and anti–corruption. Our ambition is to accelerate and scale the global collective impact of business by upholding the Ten Principles and delivering the Sustainable Development Goals through accountable companies and ecosystems that enable change. With more than 18,000 companies and 3,800 non–business signatories based in over 101 countries, and 62 Local Networks, the UN Global Compact is the world's largest corporate sustainability initiative""one Global Compact uniting business for a better world.


GLOBENEWSWIRE (Distribution ID 8950782)

]]>
The Coretec Group Releases May 2023 Shareholder Call Transcript and Webcast Recording http://www.kuwaitfinancialexpress.com/the-coretec-group-releases-may-2023-shareholder-call-transcript-and-webcast-recording/ Wed, 24 May 2023 13:13:56 +0000 http://www.kuwaitfinancialexpress.com/?p=307692 ANN ARBOR, Mich., May 24, 2023 (GLOBE NEWSWIRE) — The Coretec Group (OTCQB: CRTG), developers of silicon anode active materials for lithium–ion batteries and cyclohexasilane (CHS) for electric vehicles (EVs), cleantech, and emerging tech applications, today released the transcript and webcast recording from its May 18, 2023 shareholder update on the Company's Investor Relations Website.

During the call, The Coretec Group's Chief Executive Officer, Matt Kappers, Chief Technology Officer, Ramez Elgammal, Ph.D., and VP of Partnerships and Innovation, Michelle Tokarz, Ph.D., shared its strong results from cycling tests on its modified silicon battery material. These tests proved three important factors:

  • Coretec's team successfully bonded a polymer to the silicon nanoparticles.
  • The Endurion engineered solid electrolyte interface layer improves rate capability.
  • The cycling stability of Endurion's silicon material outperformed unmodified materials.

The Company also discussed the importance of its latest provisional patent. The patent identifies three distinct, novel methodologies for minimizing pulverization and increasing the rate capability by creating an artificial solid electrolyte interface. This innovation is capable of extending the life and increasing the capabilities of silicon–based anodes for lithium–ion batteries, with an emphasis on scalability. The development marks a major breakthrough for the Company's Endurion battery program focused on EV batteries that charge faster and last longer than the current industry standard.

The Company also provided a roadmap for the rest of the year, and an update on its current and prospective partnerships. It is developing relationships with potential Endurion end–users such as automakers and battery companies as well as key suppliers and testing companies.

The call concluded with Company leadership answering questions from the investor community. Kappers urged all who are interested in receiving the latest Company updates to sign up for notifications on its Investor Relations Website, follow the Company's social media channels on Twitter and LinkedIn, and watch its recent informational video that breaks down the Endurion battery program.

About The Coretec Group

The Coretec Group, Inc. is an Ann Arbor, Michigan–based developer of engineered silicon, working to improve lives and power the EV, cleantech, and emerging technology markets of tomorrow. The company's current battery program is Endurion; the Coretec team is applying its expertise in silicon nanoparticles to develop silicon anodes for lithium–ion batteries in EVs that will charge faster and last longer than the current industry standard.

Additionally, Coretec is also utilizing its engineered silicon to develop a portfolio of energy–focused products, including solid–state lighting (LEDs), semiconductors, 3D volumetric displays, and printable electronics. The Coretec Group's groundbreaking work is revolutionizing the EV and energy storage markets and will continue to be a pioneer in this fast–paced industry.

For more information, please visit thecoretecgroup.com.

Follow The Coretec Group on:

Twitter "" @CoretecGroupInc
LinkedIn "" www.linkedin.com/company/24789881
YouTube "" www.youtube.com/channel/UC1IA9C6PoPd1G4M7B9QiZPQ/featured

Forward–Looking Statements

The statements in this press release that relate to The Coretec Group's expectations with regard to the future impact on the Company's results from operations are forward–looking statements and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward–looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Corporate Contact:

The Coretec Group, Inc.
Lindsay McCarthy
info@thecoretecgroup.com
+1 (866) 916–0833

Media Contact:

Spencer Herrmann
FischTank PR
coretec@fischtankpr.com
+1 (518) 669–6818


GLOBENEWSWIRE (Distribution ID 8845674)

]]>